Accession Number:

AD1061925

Title:

A Proteomic Co-Clinical Trial of BGJ-398 in FGFR-Driven Biliary Cancers

Descriptive Note:

Technical Report,15 Aug 2017,14 Aug 2018

Corporate Author:

Regents of the University of California San Francisco United States

Personal Author(s):

Report Date:

2018-09-01

Pagination or Media Count:

70.0

Abstract:

Intrahepatic cholangiocarcinomas ICC is a dead malignancy of the liver bile ducts 10 5-year survival for patients of all stages with few therapeutic options for advanced disease. The project involves translational studies relating targeting the Fibroblast Growth Factor Receptor FGFR signaling pathway in ICCs harboring alterations in the FGFR pathway. FGFR alterations most commonly fusions of the FGFR2 gene that result in activation of theFGFR2 kinase are present in 20 of ICCs and clinical trials with FGFR kinase inhibitors are showing promise in these patients. However, resistance inevitably arises, limiting therapeutic efficacy. The goals of this project are to understand the basis of FGFR signaling dependency in FGFR-activated ICC, to elucidate mechanisms of clinical acquired resistance, and to improve therapeutic strategies against this subset of patients that improve initial responses and overcome resistance.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry

Distribution Statement:

APPROVED FOR PUBLIC RELEASE